Unknown

Dataset Information

0

Two Pandemics, One Challenge-Leveraging Molecular Test Capacity of Tuberculosis Laboratories for Rapid COVID-19 Case-Finding.


ABSTRACT: In many settings, the ongoing coronavirus disease (COVID-19) pandemic coincides with other major public health threats, in particular tuberculosis. Using tuberculosis (TB) molecular diagnostic infrastructure, which has substantially expanded worldwide in recent years, for COVID-19 case-finding might be warranted. We analyze the potential of using TB diagnostic and research infrastructures for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. We focused on quality control by adapting the 12 Quality System Essentials framework to the COVID-19 and TB context. We conclude that diagnostic infrastructures for TB can in principle be leveraged to scale-up SARS-CoV-2 testing, in particular in resource-poor settings. TB research infrastructures also can support sequencing of SARS-CoV-2 to study virus evolution and diversity globally. However, fundamental principles of quality management must be followed for both TB and SARS-CoV-2 testing to ensure valid results and to minimize biosafety hazards, and the continuity of TB diagnostic services must be guaranteed at all times.

SUBMITTER: Homolka S 

PROVIDER: S-EPMC7588527 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7897638 | biostudies-literature
| S-EPMC10826766 | biostudies-literature
| S-EPMC5727572 | biostudies-literature
| S-EPMC11370233 | biostudies-literature
| S-EPMC8532541 | biostudies-literature
| S-EPMC11369055 | biostudies-literature
| S-EPMC6758691 | biostudies-literature
| S-EPMC5571363 | biostudies-literature
| S-EPMC4894005 | biostudies-literature
| S-EPMC5142782 | biostudies-literature